证券代码：830839 证券简称：万通液压 公告编号：2025-079 山东万通液压股份有限公司 表决情况：同意 7 票，反对 0 票，弃权 0 票 二、 分章节列示制度主要内容： 山东万通液压股份有限公司 对外担保管理制度 第一章 总则 第一条 为加强山东万通液压股份有限公司（以下简称"公司"）的对外 担保管理，规范公司担保行为，控制和降低担保风险，保证公司资产安全， 根据依照《中华人民共和国公司法》《中华人民共和国民法典》《上市公司 监管指引第 8 号--上市公司资金往来、对外担保的监管要求》等法律、法规、 规范性文件及《山东万通液压股份有限公司章程》（以下简称"《公司章 程》"）的规定，并结合公司的实际情况，制定本制度。 对外担保管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 审议及表决情况 公司于 2025 年 9 月 19 日召开了第四届董事会第十五次会议，逐项审议 《关于修订及制定公司部分内部治理制度的议案》，通过了对《对外担保管理 制度》的修订，该制度尚需提交股东会审议。 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 审议及表决情况 证券代码：830839 证券简称：万通液压 公告编号：2025-075 山东万通液压股份有限公司 利润分配管理制度 表决情况：同意 7 票，反对 0 票，弃权 0 票 二、 分章节列示制度主要内容： 山东万通液压股份有限公司 公司于 2025 年 9 月 19 日召开了第四届董事会第十五次会议，逐项审议 《关于修订及制定公司部分内部治理制度的议案》，通过了对《利润分配管理 制度》的修订，该制度尚需提交股东会审议。 利润分配管理制度 第一章 总 则 第一条 为进一步规范山东万通液压股份有限公司(以下简称"公司")的 利润分配行为，建立和完善科学、持续、稳定的利润分配机制，增强利润分配 的透明度，保证公司长远可持续发展，切实保护中小投资者合法权益，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《上市公司监管指引第 3 号-- 上市公司现金分红（2025 修正）》《北京证券交易所上市公司持续监管指引第 10 号——权益分派》《山 ...

证券代码：830839 证券简称：万通液压 公告编号：2025-070 山东万通液压股份有限公司 关于取消监事会、减少注册资本并拟修订《公司章程》的 公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、修订内容 根据《公司法》及《上市公司章程指引》《北京证券交易所股票上市规则》等 相关规定，公司拟修订《公司章程》的部分条款，修订对照如下： | 原规定 | 修订后 | | --- | --- | | 第一条 为维护山东万通液压股份有 | 第一条 为维护山东万通液压股份有 | | 限公司（以下简称"公司"）、股东和债 | 限公司（以下简称"公司"）、股东、职 | | 权人的合法权益，规范公司的组织和 | 工和债权人的合法权益，规范公司的 | | 行为，根据《中华人民共和国公司法》 | 组织和行为，根据《中华人民共和国公 | | （以下简称"《公司法》"）、《中华人民 | 司法》（以下简称"《公司法》"）、《中华 | | 共和国证券法》（以下简称"《证券 | 人民共和国证券法》（以下简称"《证券 | | ...

一、会议召开基本情况 （一）股东会届次 本次会议为 2025 年第二次临时股东会。 证券代码：830839 证券简称：万通液压 公告编号：2025-069 山东万通液压股份有限公司 关于召开 2025 年第二次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 （二）召集人 本次股东会的召集人为董事会。 （三）会议召开的合法合规性 本次股东会的召集程序符合《公司法》《公司章程》及有关法律法规、规范 性文件的规定。本次会议的召开无需其他相关部门批准或履行必要程序。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东只能选择现场投票、网络投票中的一种方式，如果同一表 决权出现重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1.股权登记日持有公司股份的股东。 股权登记日下午收市时在中国结算登记在册的公司全体股东（具体情况详见 下表）均有权出席股东会（在股权登记日买入证券的投资者享有此权利，在股权 登记日卖出证券的投资者不享有此 ...

证券代码：830839 证券简称：万通液压 公告编号：2025-068 山东万通液压股份有限公司 第四届监事会第十三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 9 月 19 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2025 年 9 月 14 日以书面方式发出 1.议案内容： 根据《中华人民共和国公司法》《上市公司章程指引》以及《北京证券交易 所股票上市规则》等相关法律法规、规范性文件的规定，结合公司实际情况， 公司拟不再设置监事会，监事会的职权由董事会审计委员会行使。此外，公司 拟对回购专用证券账户中持有的 1,005,029 股股份予以注销，本次注销完成后， 公司注册资本将由 119,215,000 股变更为 118,209,971 股。基于上述变更，公司 拟对《公司章程》的相关条款进行修订，并提请股东会授权董事会及董事会委 派的相关人士办理工商变更登记 ...

Core Viewpoint - The article emphasizes the emergence of a new paradigm in China's economy, termed the "new new three samples," which includes robotics, artificial intelligence (AI), and innovative pharmaceuticals, as key drivers for high-quality economic development and a shift from traditional growth models to technology-led advancements [1][4][29]. Robotics Sector - The robotics sector has seen significant market capitalization growth, with companies like Huichuan Technology exceeding 200 billion yuan and several stocks doubling in price within the year [2][13]. - The market for industrial robots in China is projected to reach 302,000 units in 2024, maintaining its position as the largest industrial robot market globally [30]. - Key challenges include reliance on imported high-end servo motors and precision components, which need to be addressed to enhance domestic capabilities [33]. Artificial Intelligence Sector - The AI sector is characterized by a large number of high-value companies, with six firms exceeding a market cap of 100 billion yuan, including Cambricon and Hikvision [19]. - The demand for AI capabilities has surged, particularly in large model applications, leading to significant revenue growth for companies like Industrial Fulian and Cambricon, with year-on-year increases of 35.58% and 4347.82%, respectively [20]. - The sector is supported by national policies aimed at integrating AI into various industries, with a comprehensive action plan released to enhance AI's role in economic development [22]. Innovative Pharmaceuticals Sector - The innovative pharmaceuticals sector is represented by major players like Heng Rui Medicine, which is nearing a market cap of 500 billion yuan, and BeiGene, which recently achieved profitability [24][28]. - Recent policy measures have been introduced to support the development of innovative drugs, including streamlined approval processes and enhanced reimbursement mechanisms [27]. - The sector is witnessing a shift from loss-making to profitability, with companies like BeiGene demonstrating the commercial viability of innovative drug models [28]. Strategic Importance - The "new new three samples" signify a transition from scale-driven manufacturing to technology-driven innovation, crucial for enhancing China's global competitiveness and economic resilience [7][9][31]. - The collaboration among robotics, AI, and innovative pharmaceuticals creates a synergistic effect that strengthens overall productivity and fosters new business models [8][31]. - Addressing the "bottleneck" issues in these sectors is essential for sustaining growth and achieving leadership in global technology competition [32][33]. Policy Recommendations - To enhance competitiveness, policies should focus on data openness, regulatory reforms, and infrastructure development to support AI and innovative pharmaceuticals [35][38]. - Establishing a robust talent pipeline and fostering interdisciplinary education will be critical for sustaining innovation in these sectors [37][38]. - Encouraging public-private partnerships and international collaboration will further strengthen China's position in the global market [39].

Group 1 - Jinbo Biological has received approval from the Beijing Stock Exchange for a targeted stock issuance, with a maximum of 7.1757 million shares to be issued, aiming to raise up to 2 billion yuan [1][2] - The strategic investor for this issuance is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Biological post-issuance [2] - The funds raised will be allocated to the development of a humanized collagen FAST database and product development platform, with 1.15 billion yuan designated for this project and the remaining 850 million yuan for working capital [2] Group 2 - Yangshengtang's involvement is expected to enhance Jinbo Biological's core competitiveness and innovation capabilities, providing strategic resources for market expansion and sales performance improvement [3] - In addition to Jinbo Biological's developments, Wantong Hydraulic has also received approval for a targeted convertible bond issuance, with a maximum of 1.5 billion yuan to be raised [4] - Wantong Hydraulic plans to use the funds raised from the convertible bonds to supplement working capital, thereby alleviating financial pressure and enhancing its competitive strength in the hydraulic sector [5]

Group 1 - Jinbo Bio has received approval from the Beijing Stock Exchange for a targeted stock issuance, with a maximum of 7.1757 million shares to be issued, aiming to raise up to 2 billion yuan [1][2] - The strategic investor for this issuance is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated as follows: 1.15 billion yuan for the development of a humanized collagen FAST database and product development platform, and 850 million yuan for working capital [2] Group 2 - The collaboration with Yangshengtang is expected to enhance Jinbo Bio's core competitiveness and innovation capabilities, as well as improve market expansion and sales performance [3] - In addition to Jinbo Bio's targeted stock issuance, Wantong Hydraulic has also received approval for a targeted convertible bond issuance, with a maximum of 1.5 billion yuan to be raised [4] - Wantong Hydraulic's convertible bonds will be used entirely for working capital, addressing the company's funding needs and enhancing its competitive strength in the hydraulic sector [5]

Group 1 - Jinbo Bio has announced a private placement of shares, which has been accepted by the Beijing Stock Exchange, aiming to raise up to 2 billion yuan by issuing no more than 7.1757 million shares [1][2] - The strategic investor for this placement is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated to the development of a humanized collagen FAST database and product development platform, with 1.15 billion yuan dedicated to this project, enhancing the company's competitiveness in various medical fields [2][3] Group 2 - The private placement represents the largest scale of financing through a private placement on the Beijing Stock Exchange this year [2] - Jinbo Bio's collaboration with Yangshengtang is expected to bring advanced technological resources, enhancing core competitiveness and innovation capabilities, as well as improving market channels and brand resources [3] - Meanwhile, Wantong Hydraulic has received approval for a private convertible bond issuance, aiming to raise up to 150 million yuan to support its liquidity needs [4][5]

Group 1 - The report highlights that Jinbo Biological's private placement has been accepted, aiming to raise 2 billion for the development of a humanized collagen FAST database and product development platform, which is expected to significantly enhance the company's R&D efficiency and lay a solid foundation for long-term growth [11][12] - Wantong Hydraulic's convertible bonds have been successfully registered, with plans to raise 150 million, where Pangu Intelligent, a listed company, will subscribe for no less than 120 million [12][13] - The report emphasizes a structural market outlook for Q4, suggesting that investors should focus on core assets related to the North Exchange and manage trading rhythms effectively [12][13] Group 2 - The North Exchange 50 index fell by 1.43%, with a trading volume of 57.34 billion shares, a decrease of 13.21% week-on-week, and a trading value of 1361.69 billion yuan, down 14.73% [18][24] - The report notes that 66 stocks rose while 207 fell, resulting in a rise-fall ratio of 0.32, with notable gainers including Kaiter Co. (+33.76%) and Sanwei Equipment (+22.53%) [38][39] - The average PE (TTM) for the North Exchange is 87.36 times, with a median of 49.68 times, indicating a decrease in valuation metrics [24][25] Group 3 - The report mentions that 10 new companies were listed on the New Third Board, while 5 were delisted, with a total planned financing of 362 million yuan and completed financing of 133 million yuan [47][48] - The newly listed company, Shichang Co., had a first-day increase of 271.56%, with a trading volume of 6.41 billion yuan [26][30] - The report indicates that the New Third Board currently has 6021 listed companies, with 2319 in the innovation layer and 3702 in the basic layer [47]